Association between polymorphisms of the DNA repair genes RAD51 and OGG1 and risk of cardiovascular disease

被引:1
作者
Alomair, Amar [1 ]
Alamri, Abdullah [1 ]
Shaik, Jilani [1 ]
Aljafari, Salman [2 ]
Abdullah, Mohammed Ba [3 ]
Alanazi, Mohammad [1 ]
机构
[1] King Saud Univ, Coll Sci, Genome Res Chair, Dept Biochem, Thleem Rd, Riyadh 11451, Saudi Arabia
[2] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh 11481, Saudi Arabia
[3] King Faisal Univ, Coll Sci, Dept Biol Sci, Al Hasa 31982, Saudi Arabia
关键词
OGG1; RAD51; DNA repair; polymorphism; cardiovascular disease; 5' UNTRANSLATED REGION; BASE-EXCISION-REPAIR; CANCER RISK; BREAST-CANCER; LUNG-CANCER; DAMAGE; ATHEROSCLEROSIS; MECHANISMS; XRCC1;
D O I
10.3892/mmr.2024.13177
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cardiovascular disease (CVD) is one of the leading causes of mortality worldwide, and multiple single-nucleotide polymorphisms of DNA repair genes have been found to be associated with CVD. The aim of the present study was to assess the effects of the genetic variants of RAD51 recombinase (RAD51) and 8-oxoguanine DNA glycosylase (OGG1) on CVD through genotyping and statistical analysis. Regardless of whether there is a significant association or not, the genotyping data on these two polymorphisms are valuable, because there is limited availability of it in certain populations. A total of 240 blood samples were analyzed and genotyped using TaqMan genotyping; 120 were obtained from cases with a history of CVD, and 120 from cases with no history of CVD. A questionnaire was administered to gather information on age, demographics, sex and clinical features, and confirmation was carried out using medical records. The results of the present study confirmed that the polymorphism rs1052133 in OGG1 had no significant association with CVD. On the other hand, the polymorphism rs1801321 in RAD51 exhibited a significant association with CVD. Collectively, the results of the present study revealed that the polymorphism rs1801321 in RAD51 exhibited a significant association with CVD, however a larger sample size to confirm the present findings, may allow for the early identification of CVD and may aid in the decision-making process concerning treatments for CVD.
引用
收藏
页数:8
相关论文
共 39 条
[11]   SHARED RISK-FACTORS FOR CANCER AND ATHEROSCLEROSIS - A REVIEW OF THE EPIDEMIOLOGIC EVIDENCE [J].
HANSEN, ES .
MUTATION RESEARCH, 1990, 239 (03) :163-179
[12]   The DNA damage response: Ten years after [J].
Harper, J. Wade ;
Elledge, Stephen J. .
MOLECULAR CELL, 2007, 28 (05) :739-745
[13]  
Hassan Fathelrahman M, 2019, Asian Pac J Cancer Prev, V20, P925, DOI 10.31557/APJCP.2019.20.3.925
[14]  
Hasselbach L, 2005, EUR J GYNAECOL ONCOL, V26, P589
[15]   Formation, prevention, and repair of DNA damage by iron hydrogen peroxide [J].
Henle, ES ;
Linn, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (31) :19095-19098
[16]   Synergistic Effects of Polymorphisms in DNA Repair Genes and Endogenous Estrogen Exposure on Female Breast Cancer Risk [J].
Hsu, Ming-Shiean ;
Yu, Jyh-Cherng ;
Wang, Hsiao-Wei ;
Chen, Shou-Tung ;
Hsiung, Chia-Ni ;
Ding, Shian-ling ;
Wu, Pei-Ei ;
Shen, Chen-Yang ;
Cheng, Chun-Wen .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (03) :760-771
[17]   Genetic Polymorphism of DNA Base-excision Repair Genes (APE1, OGG1 and XRCC1) and Their Correlation with Risk of Lung Cancer in a Chinese Population [J].
Li, Zheng ;
Guan, Wei ;
Li, Meng-xia ;
Zhong, Zhao-yang ;
Qian, Cheng-yuan ;
Yang, Xue-qin ;
Liao, Ling ;
Li, Zeng-peng ;
Wang, Dong .
ARCHIVES OF MEDICAL RESEARCH, 2011, 42 (03) :226-234
[18]   RAD51, BRCA2 and DNA repair: a partial resolution [J].
Lord, Christopher J. ;
Ashworth, Alan .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (06) :461-462
[19]   Association of polymorphisms in the 5′ untranslated region of RAD51 gene with risk of endometrial cancer in the Polish population [J].
Michalska, Magdalena M. ;
Samulak, Dariusz ;
Romanowicz, Hanna ;
Smolarz, Beata .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (05) :985-991
[20]   DNA Repair: Translation to the Clinic [J].
Minten, E., V ;
Yu, D. S. .
CLINICAL ONCOLOGY, 2019, 31 (05) :303-310